TaiRx, Inc. (6580.TWO)
- Previous Close
24.00 - Open
24.10 - Bid 23.25 x --
- Ask 24.10 x --
- Day's Range
24.10 - 24.10 - 52 Week Range
17.40 - 44.00 - Volume
2 - Avg. Volume
99,743 - Market Cap (intraday)
2.665B - Beta (5Y Monthly) 0.55
- PE Ratio (TTM)
-- - EPS (TTM)
-1.26 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company's products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in treatment of selenium deficiency; and focuses on development of the nodal diagnostic devices and anti-body drugs. TaiRx, Inc. was founded in 2011 and is based in Taipei City, Taiwan.
www.trx.com.twRecent News: 6580.TWO
View MorePerformance Overview: 6580.TWO
Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6580.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6580.TWO
View MoreValuation Measures
Market Cap
2.65B
Enterprise Value
2.15B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
321.78
Price/Book (mrq)
4.10
Enterprise Value/Revenue
261.57
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-20.13%
Return on Equity (ttm)
-33.65%
Revenue (ttm)
5.32M
Net Income Avi to Common (ttm)
-183.76M
Diluted EPS (ttm)
-1.26
Balance Sheet and Cash Flow
Total Cash (mrq)
573.84M
Total Debt/Equity (mrq)
1.51%
Levered Free Cash Flow (ttm)
-108.8M